347 related articles for article (PubMed ID: 10506707)
21. An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia.
Aldoss I; Pullarkat V; Patel R; Watkins K; Mohrbacher A; Levine AM; Douer D
Med Oncol; 2013 Dec; 30(4):744. PubMed ID: 24135867
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period.
Thomas X; Danaïla C; Le QH; Sebban C; Troncy J; Charrin C; Lhéritier V; Michallet M; Magaud JP; Fiere D
Leukemia; 2001 Dec; 15(12):1811-22. PubMed ID: 11753600
[TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
26. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
Ko RH; Ji L; Barnette P; Bostrom B; Hutchinson R; Raetz E; Seibel NL; Twist CJ; Eckroth E; Sposto R; Gaynon PS; Loh ML
J Clin Oncol; 2010 Feb; 28(4):648-54. PubMed ID: 19841326
[TBL] [Abstract][Full Text] [Related]
27. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
28. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Pfeifer H; Scheuring U; Klein SA; Gökbuget N; Binckebanck A; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2002 Dec; 16(12):2358-65. PubMed ID: 12454740
[TBL] [Abstract][Full Text] [Related]
29. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.
Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E
Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
31. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
32. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
33. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Dombret H; Gabert J; Boiron JM; Rigal-Huguet F; Blaise D; Thomas X; Delannoy A; Buzyn A; Bilhou-Nabera C; Cayuela JM; Fenaux P; Bourhis JH; Fegueux N; Charrin C; Boucheix C; Lhéritier V; Espérou H; MacIntyre E; Vernant JP; Fière D;
Blood; 2002 Oct; 100(7):2357-66. PubMed ID: 12239143
[TBL] [Abstract][Full Text] [Related]
34. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
35. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.
Thomas X; Boiron JM; Huguet F; Dombret H; Bradstock K; Vey N; Kovacsovics T; Delannoy A; Fegueux N; Fenaux P; Stamatoullas A; Vernant JP; Tournilhac O; Buzyn A; Reman O; Charrin C; Boucheix C; Gabert J; Lhéritier V; Fiere D
J Clin Oncol; 2004 Oct; 22(20):4075-86. PubMed ID: 15353542
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
37. [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia].
Huang J; Zou DH; Fu MW; Li ZJ; Xu Y; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):673-8. PubMed ID: 22339825
[TBL] [Abstract][Full Text] [Related]
38. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
Kantarjian HM; Thomas D; Ravandi F; Faderl S; Jabbour E; Garcia-Manero G; Pierce S; Shan J; Cortes J; O'Brien S
Cancer; 2010 Dec; 116(24):5568-74. PubMed ID: 20737576
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
40. Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
Reman O; Buzyn A; Lhéritier V; Huguet F; Kuentz M; Stamatoullas A; Delannoy A; Fegueux N; Micléa JM; Boiron JM; Vernant JP; Gardin C; Hacini M; Georges M; Fière D; Thomas X;
Hematol J; 2004; 5(2):123-9. PubMed ID: 15048062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]